In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the
literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” …

Since the initial description of the disease, the life-threatening coagulopathy associated with
acute promyelocytic leukaemia (APL) has been the defining clinical characteristic …

Our knowledge about acute promyelocytic leukemia (APL) patients is mainly based on data
from clinical trials, whereas population-based information is scarce. We studied APL patients …

Acute promyelocytic leukemia is the first malignant disease highly curable with targeted
therapy directed at a unique molecular abnormality. The characteristic bleeding diathesis is …

Thanks to modern treatment with all-trans retinoic acid and chemotherapy, acute
promyelocytic leukemia (APL) is now the most curable type of leukemia. However, this …

Early mortality in acute promyelocytic leukemia has been reported to occur in less than 10%
of patients treated in clinical trials. This study reports the incidence and clinical features of …

Despite therapeutic advances, early death (ED) remains a major factor curtailing survival of
acute promyelocytic leukemia (APL). Studies examining factors that cause early death (ED; …

Acute promyelocytic leukemia (APL) is a hyper-acute illness and presents with profound
cytopenias in most patients and disseminated intravascular coagulation (DIC). Excellent …

Arsenic Trioxide is an old drug that has recently re-introduced into new medicine. It is very
potent against a specific type of leukemic cells harboring translocation between …

Background The epidemiology and treatment of acute promyelocytic leukaemia (APL) are
changing. We have incorporated oral arsenic trioxide (oral-ATO) into induction/maintenance …